Uplarafenib

Cat. No.: HY-148059

CAS No.: 1425485-87-5

Molecular Formula: $C_{22}H_{21}F_3N_4O_4S$

Molecular Weight: 494.49

Target: Raf

Pathway: MAPK/ERK Pathway

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (202.23 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0223 mL	10.1114 mL	20.2229 mL
	5 mM	0.4045 mL	2.0223 mL	4.0446 mL
	10 mM	0.2022 mL	1.0111 mL	2.0223 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC_{50} between 50 and 100 nM. Uplarafenib shows antitumor activity[1].

IC_{50} & Target

BRAF-V600E	Braf
< 50 nM (IC_{50})	50-100 nM (IC_{50})

In Vitro

Uplarafenib (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E[1].
Uplarafenib shows an IC_{50} between 50 and 100 nM against BRAF, less than 50 nM against BRAF V600E[1].
Uplarafenib (72 h) inhibits A375 and SK-MEL-28 cells growth but not CHL-1 and SK-MEL-31 cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	A375, SK-MEL-28, SK-MEL-31 and CHL-1
Concentration:	

Incubation Time:	72 h
Result:	Showed inhibition with IC_{50}s less than 500 nM against A375 and SK-MEL-28 cells, and showed no inhibition against CHL-1 and SK-MEL-31.

REFERENCES

[1]. Yong-Liang Zhu, et al. Certain Chemical Entities, Compositions, and Methods. Patent US20130053384 A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA